1. Home
  2. ACRS vs BLMN Comparison

ACRS vs BLMN Comparison

Compare ACRS & BLMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.35

Market Cap

608.9M

Sector

Health Care

ML Signal

HOLD

Logo Bloomin' Brands Inc.

BLMN

Bloomin' Brands Inc.

HOLD

Current Price

$8.60

Market Cap

714.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRS
BLMN
Founded
2012
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
608.9M
714.0M
IPO Year
2015
2012

Fundamental Metrics

Financial Performance
Metric
ACRS
BLMN
Price
$5.35
$8.60
Analyst Decision
Strong Buy
Hold
Analyst Count
5
8
Target Price
$10.20
$7.88
AVG Volume (30 Days)
2.0M
2.2M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
4.99%
EPS Growth
69.01
106.71
EPS
N/A
0.65
Revenue
$1,683,000.00
$4,213,346,000.00
Revenue This Year
N/A
$2.07
Revenue Next Year
$4.24
$1.81
P/E Ratio
N/A
$12.99
Revenue Growth
N/A
N/A
52 Week Low
$1.46
$5.19
52 Week High
$5.85
$10.70

Technical Indicators

Market Signals
Indicator
ACRS
BLMN
Relative Strength Index (RSI) 55.46 56.58
Support Level $4.13 $7.06
Resistance Level $5.85 $8.70
Average True Range (ATR) 0.31 0.50
MACD -0.01 -0.03
Stochastic Oscillator 50.00 57.28

Price Performance

Historical Comparison
ACRS
BLMN

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

About BLMN Bloomin' Brands Inc.

Bloomin Brands Inc is a casual dining restaurant company, with a portfolio of, differentiated restaurant concepts. Its restaurant portfolio includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill and Fleming's Prime Steakhouse & Wine Bar. Its restaurant concepts range in price point and degree of formality from casual (Outback Steakhouse and Carrabba's Italian Grill) to polished casual (Bonefish Grill) and fine dining (Fleming's Prime Steakhouse & Wine Bar). The U.S. segment includes all restaurants operating in the U.S. while franchised restaurants operating outside the U.S. are included in the international franchise segment.

Share on Social Networks: